Results 111 to 120 of about 34,445,663 (284)

A framework for integrating health‐related social needs education into electronic health record clinical pathways

Journal of Hospital Medicine, EarlyView.
Abstract Health‐related social needs (HRSN) significantly influence patient outcomes, yet they are rarely integrated into point‐of‐care decision‐making. We developed a process to embed HRSN‐informed and HRSN‐targeted care recommendations directly into three electronic health record‐integrated high‐use clinical pathways—cirrhosis, diabetes, and ...
Karthik Warke Rohatgi, Siddhi Nadkarni, Nisarg Shah, Lou Hart, Dan Heacock, Shaili Gupta   +5 more
wiley   +1 more source

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues

Molecular Metabolism
Objectives: Unimolecular triagonists drive substantial weight loss in patients with obesity by engaging the glucagon-like peptide 1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide receptor (GIPR) to reduce food intake (FI) and the ...
Jonathan D. Douros, Megan Capozzi, Aaron Novikoff, Jacek Mokrosinski, Barent DuBois, Joseph Stock, Rebecca Rohlfs, Mikayla Anderson, Dominika J. Jedrzejcyk, Svend Poulsen, Erik Oude Blenke, Tomas Dago, Kasper Huus, Peder L. Nørby, Sune Kobberup, Marita Rivir, Joyce Sorrell, Stephanie A. Mowery, Daniel J. Drucker, David A. D'Alessio, Jonathan E. Campbell, Timo D. Müller, Diego Perez-Tilve, Brian Finan, Patrick J. Knerr   +24 more
doaj   +1 more source

Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists

Diabetes & Metabolism
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, secreted from gut endocrine cells, which acts to potentiate nutrient-induced insulin secretion. Activation of its receptor, GLP-1R, decreases glucagon secretion and gastric emptying, thereby decreasing blood glucose and body weight. It is largely through these mechanisms that Glucagon-like peptide-
J Chen, ME Cooper, MT Coughlan
openaire   +2 more sources

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Shaping the research agenda of pediatric gastroenterology, hepatology, and nutrition: The proposal from an Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) expert group

JPGN Reports, EarlyView.
Abstract The Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) recognized the need to define research priorities and identify knowledge gaps to guide future investigations in pediatric digestive health. Following international examples, SIGENP aimed to provide a structured framework that aligns scientific innovation with ...
Carlo Agostoni, Daniele Alberti, Renata Auricchio, Maria Elisabetta Baldassarre, Osvaldo Borrelli, Matteo Bramuzzo, Teresa Capriati, Carlo Catassi, Sabrina Cenni, Marco Crocco, Salvatore Cucchiara, Luigi Dall'Oglio, Paola De Angelis, Marco Deganello Saccomani, Fabiola Di Dato, Angelo Di Giorgio, Antonella Diamanti, Valeria Dipasquale, Enrico Felici, Ruggiero Francavilla, Valentina Giorgio, Luigi Greco, Raffaele lorio, Flavio Labriola, Paolo Lionetti, Elena Lionetti, Giuseppe Maggiore, Monica Malamisura, Claudia Mandato, Antonio Marseglia, Emanuele Nicastro, Lorenzo Norsa, Salvatore Oliva, Licia Pensabene, Elena Sofia Pieri, Paolo Quitadamo, Giusy Ranucci, Sara Renzo, Claudio Romano, Silvia Salvatore, Luca Scarallo, Maria Immacolata Spagnuolo, Annamaria Staiano, Caterina Strisciuglio, Renato Tambucci, Riccardo Troncone, Pietro Vajro   +46 more
wiley   +1 more source

Obesity and hypertension in type 2 diabetes: exploring central and peripheral effects of glucagon-like peptide-1 receptor signalling

Glucagon-like peptide 1 is a hormone involved in the regulation of glucose. Glucose-dependent activation of brain GLP-1R stimulates GLP-1 secretion from the L-cells of the intestine in response to ingested nutrients and it enters the blood stream to ...
Robinson, Louise E.
core  

Glucagon like peptide 1 receptor agonists: therapy for diabetes management

, 2017
Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.
Granados Vega, Elkyn Johan, Rojas, Natalia Andrea   +1 more
core   +1 more source

Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series

JPGN Reports, EarlyView.
Abstract Pediatric obesity and metabolic dysfunction‐associated steatotic liver disease (MASLD) prevalence has risen markedly over the past decade. Due to transition delays and workforce shortages, pediatric specialists often manage patients into young adulthood, and thus familiarity with adult pharmacotherapies for MASLD is essential.
Brandon J. Perumpail, Andrea Tou, Jennifer Panganiban   +2 more
wiley   +1 more source

Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?

Introduction Parkinson’s disease (PD) is a common neurodegenerative disease. Glucagon-like peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD and are being considered for the treatment of PD.
Doggrell, Sheila A
core   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source